These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24510469)

  • 21. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D; Gershenzon A; Corallo CE; Nagappan R
    Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
    Kounas SP; Letsas KP; Sideris A; Efraimidis M; Kardaras F
    Pacing Clin Electrophysiol; 2005 May; 28(5):472-3. PubMed ID: 15869686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
    Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
    Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
    Kiblboeck D; Braeuer-Mocker M; Siostrzonek P; Reisinger J
    BMJ Case Rep; 2012 Aug; 2012():. PubMed ID: 22927286
    [No Abstract]   [Full Text] [Related]  

  • 25. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
    Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
    Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation].
    Karch M; Schmitt C; Plewan A; Schmidt G; Schömig A
    Herz; 1997 Feb; 22(1):51-6. PubMed ID: 9173039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].
    Antonelli D; Feldman A; Freedberg NA; Darawsha A; Rosenfeld T
    Harefuah; 2006 May; 145(5):342-4, 398. PubMed ID: 16805213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
    Taylor R; Gandhi MM; Lloyd G
    BMJ; 2010 Mar; 340():b4684. PubMed ID: 20219811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proarrhythmic effects of antiarrhythmic drugs.
    Zipes DP
    Am J Cardiol; 1987 Apr; 59(11):26E-31E. PubMed ID: 2437787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.
    Alboni P; Botto GL; Boriani G; Russo G; Pacchioni F; Iori M; Pasanisi G; Mancini M; Mariconti B; Capucci A
    Heart; 2010 Apr; 96(7):546-9. PubMed ID: 20350992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of patients with acute atrial fibrillation in the ED.
    Conti A; Del Taglia B; Mariannini Y; Pepe G; Vanni S; Grifoni S; Abbate R; Michelucci A; Padeletti L; Gensini GF
    Am J Emerg Med; 2010 Oct; 28(8):903-10. PubMed ID: 20825922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
    Zarembski DG; Nolan PE; Slack MK; Caruso AC
    Arch Intern Med; 1995 Sep; 155(17):1885-91. PubMed ID: 7677555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short QT syndrome: pharmacological treatment.
    Gaita F; Giustetto C; Bianchi F; Schimpf R; Haissaguerre M; Calò L; Brugada R; Antzelevitch C; Borggrefe M; Wolpert C
    J Am Coll Cardiol; 2004 Apr; 43(8):1494-9. PubMed ID: 15093889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
    Alboni P; Botto GL; Baldi N; Luzi M; Russo V; Gianfranchi L; Marchi P; Calzolari M; Solano A; Baroffio R; Gaggioli G
    N Engl J Med; 2004 Dec; 351(23):2384-91. PubMed ID: 15575054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.
    Khan IA; Gowda RM
    Int J Cardiol; 2004 May; 95(1):1-6. PubMed ID: 15159030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome.
    Hallman K; Carlsson L
    Pharmacol Toxicol; 1995 Oct; 77(4):250-4. PubMed ID: 8577635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of flecainide-induced hyponatremia.
    Ahmed M; Sra J; Akhtar M; Mortada ME
    J Cardiovasc Electrophysiol; 2009 Oct; 20(10):1170-2. PubMed ID: 19298558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.